CancerNetwork: Illuminating Optimal CAR T-Cell Therapies Across Large B-Cell Lymphoma Groups
The post CancerNetwork: Illuminating Optimal CAR T-Cell Therapies Across Large B-Cell Lymphoma Groups appeared first on UNC Lineberger Comprehensive Cancer Center .
Read the full articleYou might also wanna read
AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers
An AI-guided framework integrating high-resolution cellular atlases, public knowledge databases, and large language models enables a modular
Resetting autoimmune disease with CAR cell therapies
Explore the potential of CAR T cells in autoimmune diseases: a novel way to target B cells, reset immunity, and meet clinical gaps! PMID:421
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
Conditions : CLDN18.2 Positive Solid Tumors Interventions : Biological: SUV2208A cell injection; Biological: SUV2208A; Biological: SUV2208A
Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells
Nature, Published online: 01 July 2026; doi:10.1038/s41586-026-10641-1 Integrated multi-omic profiling of glioblastoma reveals GPNMB as a sh
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
Conditions : Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Hairy Cell Leukemia; Multiple Myeloma Interventions : Biological: LMY-922 S
Yan Leyfman on CAR T-Cell Resistance and the Tumor Microenvironment
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn: “Targeting tumor-associated m
Comments
Sign in to join the conversation.
No comments yet. Be the first.